Developer docs
API playgroundTry for free, no card

Search company profiles

Bendalis

Full company profile

uuid000mpq2

Namestring
Bendalis
Legal namestring
Bendalis GmbH
Websiteurl
bendalis.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Bendalis GmbH is a privately held German specialty pharmaceutical company founded in 2006 and headquartered in Oberhaching near Munich. The company develops, manufactures, and markets a portfolio of high-quality sterile generic oncology drugs, supportive care products, and selected antibiotics for the hospital and clinical sector. Its product range spans approximately 20 active ingredients, including established chemotherapy agents (5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine), bisphosphonates (Zoledronic acid, Ibandronic acid), Somatostatin Lyomark 3 mg, Sugammadex (acquired with worldwide distribution rights from Biofactor effective January 2025), and Vancomycin, alongside supportive care lines such as Bendafolin, the AgainLife sub-brand based on patented Adelmidrol, KapDolen, and co-distributed products Caphosol and ALOXI.

Manufacturing is conducted under GMP and GDP certification, with a production licence from the Government of Upper Bavaria and product approvals from the Federal Institute for Drugs and Medical Devices (BfArM). Manufacturing is split between Germany, via the sister company Lyomark Pharma GmbH (a contract and active ingredient manufacturer founded in 1989 and sharing dual management with Bendalis), and an additional production facility in Spain integrated into the approval system in 2026. A documented dual-sourcing strategy is used for active ingredients to ensure supply continuity.

Bendalis does not sell directly to consumers. Commercialisation occurs through a hybrid enterprise model combining direct sales engagement by an in-house scientific and sales team with exclusive and regional distribution partnerships, notably the Inceptua Group for global clinical trial supply and Inresa Arzneimittel for German hospitals. Target customers are hospitals, oncology and haematology clinics, hospital pharmacies, clinical research organisations, and pharmaceutical trial sponsors across Europe, North America, and Asia. End markets are fragmented (thousands of hospitals and 8,000+ active oncology studies served indirectly through Inceptua), and revenue is not publicly disclosed.

Short descriptiontext

Bendalis GmbH is a German specialty pharmaceutical company that develops, manufactures, and markets GMP-certified sterile generic oncology drugs and supportive care products for hospitals and clinical trial sponsors across Europe and international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOberhaching, Germany
HQ citystring
Oberhaching
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic oncology drugs, sterile pharmaceutical manufacturing, supportive care products, hospital pharmaceuticals, chemotherapy medications
Industry1 code
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Oncology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sale of sterile oncology medicines, generic cancer drugs, supportive care products, and specialist therapeutics to hospitals, clinics, and healthcare providers. Products include 5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Epirubicin, Gemcitabine, Irinotecan, Octreotide, Oxaliplatin, Vinorelbine, Zoledronic acid, Ibandronic acid, Bendafolin, Sugammadex, Vancomycin, Somatostatin Lyomark 3 mg, and the AgainLife supportive care product line. Revenue is generated through direct sales and distribution partnerships globally.

bendalis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1AgainLife
Description

Supportive care product line including OraLife, TraLife, RaLife, EvaLife, and GutLife.

bendalis.com
Core offering1 text field

Bendalis manufactures and markets a broad portfolio of generic sterile oncology chemotherapy agents (5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine), supportive care products (Bendafolin, the AgainLife product line based on Adelmidrol, KapDolen), and specialty therapeutics (Sugammadex, Somatostatin Lyomark 3 mg, Vancomycin). Products are produced to European GMP/GDP quality standards at sterile manufacturing sites in Germany and Spain and supplied to hospitals, oncology clinics, hospital pharmacies, and clinical trial sponsors across Europe, North America and Asia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bendalis is a specialty pharmaceutical company focused on the development and marketing of high-quality generic oncology drugs and supportive care products for the hospital sector. The company operates a diversified portfolio centered around three main product categories: (1) Core Oncology Products - a broad range of established generic chemotherapy agents including 5-Fluorouracil (5FU), Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine, Octreotide, Zoledronic acid, Ibandronic acid, Somatostatin Lyomark 3 mg, and Sugammadex (acquired 2025); (2) Supportive Care Products including Bendafolin (folinic acid), the Again-Life sub-brand product line (OraLife, TraLife, RaLife, EvaLife, GutLife) for skin and mucous membrane protection using Adelmidrol, KapDolen for nerve fibre relief, and distributed products Caphosol (oral mucositis) and ALOXI (antiemetic); and (3) Antibiotics including Vancomycin. Products are manufactured to European quality standards with GMP and GDP certification and are distributed primarily to hospitals and clinical settings across Europe and internationally.

Product and service22 records
15-Fluorouracil (5FU)
CategoryCore Oncology (Chemotherapy)
Description

Generic fluoropyrimidine chemotherapy medication used in the treatment of various solid tumours including colorectal, gastric, breast, and pancreatic cancers; available in 10-pack presentations.

2Carboplatin
CategoryCore Oncology (Chemotherapy)
Description

Generic platinum-based chemotherapy agent used to treat ovarian cancer, lung cancer, and other solid tumours.

3Doxorubicin
CategoryCore Oncology (Chemotherapy)
Description

Anthracycline chemotherapy medication used to treat a wide range of cancers including bladder, breast, lymphoma, and other malignancies.

4Methotrexate
CategoryCore Oncology (Chemotherapy)
Description

Antimetabolite and antifolate chemotherapy drug used in various cancers and autoimmune conditions, also used in oncology supportive care.

5Paclitaxel
CategoryCore Oncology (Chemotherapy)
Description

Taxane chemotherapy medication used to treat various solid tumours including breast, ovarian, and lung cancer.

6Docetaxel
CategoryCore Oncology (Chemotherapy)
Description

Taxane chemotherapy medication used in breast, lung, and prostate cancer; supplied via Inceptua for global clinical trial use.

7Gemcitabine
CategoryCore Oncology (Chemotherapy)
Description

Nucleoside analog chemotherapy used in pancreatic, breast, lung, ovarian, and bladder cancer; supplied via Inceptua for clinical trial use.

8Epirubicin
CategoryCore Oncology (Chemotherapy)
Description

Anthracycline chemotherapy medication used primarily in breast cancer and other solid tumours.

9Irinotecan
CategoryCore Oncology (Chemotherapy)
Description

Topoisomerase I inhibitor chemotherapy used primarily in metastatic colorectal cancer; supplied via Inceptua for clinical trial use.

10Oxaliplatin
CategoryCore Oncology (Chemotherapy)
Description

Platinum-based chemotherapy used in combination regimens for colorectal cancer; supplied via Inceptua for clinical trial use.

11Vinorelbine
CategoryCore Oncology (Chemotherapy)
Description

Vinca alkaloid chemotherapy used primarily in non-small cell lung cancer and breast cancer; supplied via Inceptua for clinical trial use.

12Octreotide
CategoryCore Oncology (Specialty Therapeutics)
Description

Synthetic somatostatin analog used in the treatment of neuroendocrine tumours, acromegaly, and related conditions.

13Zoledronic acid
CategoryOncology Supportive Care
Description

Bisphosphonate used to treat bone metastases and tumour-induced hypercalcemia of malignancy.

14Ibandronic acid
CategoryOncology Supportive Care
Description

Bisphosphonate used in oncology-related bone metastases and osteoporosis care.

15Somatostatin Lyomark 3 mg
CategoryCore Oncology (Specialty Therapeutics)
Description

Somatostatin analog supplied in 3 mg vials for treatment of neuroendocrine tumours, gastrointestinal bleeding, and related hospital indications.

16Sugammadex
CategoryAnesthesia / Surgical Specialty
Description

Selective relaxant binding agent used to reverse neuromuscular blockade induced by rocuronium or vecuronium during surgery; now distributed globally by Bendalis with full worldwide rights.

17Vancomycin Bendalis
CategoryAntibiotic (Hospital Specialty)
Description

Glycopeptide antibiotic supplied in 500 mg and 1000 mg 10-packs for treatment of serious Gram-positive infections in hospital settings.

18Bendafolin (Folinic acid)
CategoryOncology Supportive Care
Description

Folinic acid (leucovorin) used as rescue therapy after high-dose methotrexate and to enhance 5-fluorouracil activity in colorectal cancer regimens.

19AgainLife Product Line (OraLife, TraLife, RaLife, EvaLife, GutLife)
CategoryOncology Supportive Care
Description

Medical device product line for skin and mucous membrane protection during cancer therapy, based on the patented active ingredient Adelmidrol; includes OraLife and TraLife (oral rinses/sprays), RaLife (skin cream), EvaLife (vaginal gel), and GutLife (anal cream).

20KapDolen
CategoryOncology Supportive Care
Description

Supportive care product for relief of damaged tissues and nerve fibres in cancer patients; available in 30 ml and 100 ml presentations.

21Caphosol
CategoryOncology Supportive Care
Description

Calcium phosphate oral rinse distributed by Bendalis (in partnership with EUSA Pharma) for the management of oral mucositis caused by cancer therapy.

22ALOXI (Palonosetron)
CategoryOncology Supportive Care
Description

Innovative 5-HT3 receptor antagonist used for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV); co-promoted by Bendalis with Riemser Arzneimittel AG in Germany.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-01
Description

Bendalis GmbH acquired the product Sugammadex completely including all global distribution rights from Biofactor GmbH effective 1 January 2025. All existing customer relationships, contractual rights, and distribution structures transferred to Bendalis, creating a single point of contact for supply, quality, and support worldwide. The acquisition marks a significant expansion of Bendalis international activities.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-08
Description

Bendalis GmbH partnered with Inresa Arzneimittel GmbH as the distribution and sales partner for Somatostatin Lyomark 3 mg in Germany. Inresa was chosen as a strategic distributor to ensure continued supply of Somatostatin and maintain patient care. The product is now supplied in vials instead of ampoules, improving safety and reducing glass breakage. Inresa is established in hospitals and known for reliable on-time deliveries.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-11-25
Description

Bendalis entered an exclusive agreement with Inceptua Group (formerly Multipharma GmbH) for the supply of clinical trial material for generic oncology products. Inceptua became the exclusive worldwide distributor of Bendalis products for clinical trials, offering sponsors rapid access to Brexit-compliant oncology standard of care medicines manufactured within the EU. Products include Carboplatin, Docetaxel, Gemcitabine, Paclitaxel, Oxaliplatin, Vinorelbine, Irinotecan, and Fluorouracil (5FU). The partnership enables Bendalis to serve clinical trial sponsors globally through Inceptua's established network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lyomark Pharma GmbH is the sister company of Bendalis, founded in 1989 in Oberhaching near Munich as a contract and active ingredient manufacturer for niche products. Lyomark provides lyophilised and liquid sterile product manufacturing services to Bendalis. Services include dossier provision, maintenance, and submission of national and international approvals for pharmaceutical companies. The companies share management (Dr. Wolfgang Burger and Dr. Dirk Hütten serve as Managing Directors of both entities).

5EUSA Pharma GmbH
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

In 2008, Bendalis entered a collaboration with EUSA Pharma GmbH for the distribution of Caphosol for the treatment of oral mucositis, a supportive care product for cancer patients.

bendalis.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

From the beginning of 2011, Bendalis had a co-promotion agreement with Riemser Arzneimittel AG for Aloxi (Palonosetron), an innovative 5-HT3 receptor antagonist for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This partnership was for the German market.

7European, North American and Asian Strategic Partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Bendalis has strategic alliances with partners in Europe, North America and Asia to continuously expand global reach. These partnerships focus on collaborative innovation to drive new therapies and standards in oncology. The company is seeking additional partners who share their values to advance oncology therapeutics.

bendalis.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bendalis

Specialty Oncology Pharmaceuticalsbendalis.com

Bendalis GmbH is a German specialty pharmaceutical company that develops, manufactures, and markets GMP-certified sterile generic oncology drugs and supportive care products for hospitals and clinical trial sponsors across Europe and international markets.

What Bendalis does

Bendalis GmbH is a privately held German specialty pharmaceutical company founded in 2006 and headquartered in Oberhaching near Munich. The company develops, manufactures, and markets a portfolio of high-quality sterile generic oncology drugs, supportive care products, and selected antibiotics for the hospital and clinical sector. Its product range spans approximately 20 active ingredients, including established chemotherapy agents (5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine), bisphosphonates (Zoledronic acid, Ibandronic acid), Somatostatin Lyomark 3 mg, Sugammadex (acquired with worldwide distribution rights from Biofactor effective January 2025), and Vancomycin, alongside supportive care lines such as Bendafolin, the AgainLife sub-brand based on patented Adelmidrol, KapDolen, and co-distributed products Caphosol and ALOXI.

Manufacturing is conducted under GMP and GDP certification, with a production licence from the Government of Upper Bavaria and product approvals from the Federal Institute for Drugs and Medical Devices (BfArM). Manufacturing is split between Germany, via the sister company Lyomark Pharma GmbH (a contract and active ingredient manufacturer founded in 1989 and sharing dual management with Bendalis), and an additional production facility in Spain integrated into the approval system in 2026. A documented dual-sourcing strategy is used for active ingredients to ensure supply continuity.

Bendalis does not sell directly to consumers. Commercialisation occurs through a hybrid enterprise model combining direct sales engagement by an in-house scientific and sales team with exclusive and regional distribution partnerships, notably the Inceptua Group for global clinical trial supply and Inresa Arzneimittel for German hospitals. Target customers are hospitals, oncology and haematology clinics, hospital pharmacies, clinical research organisations, and pharmaceutical trial sponsors across Europe, North America, and Asia. End markets are fragmented (thousands of hospitals and 8,000+ active oncology studies served indirectly through Inceptua), and revenue is not publicly disclosed.

Bendalis firmographics

Firmographics
Name
Bendalis
Legal name
Bendalis GmbH
Website
https://bendalis.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Bendalis GmbH is a German specialty pharmaceutical company that develops, manufactures, and markets GMP-certified sterile generic oncology drugs and supportive care products for hospitals and clinical trial sponsors across Europe and international markets.
Ownership category
akta.pro rank

Bendalis industry classification

Industry
Product category
Specialty Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Generic oncology drugs
  • Sterile pharmaceutical manufacturing
  • Supportive care products
  • Hospital pharmaceuticals
  • Chemotherapy medications

Where Bendalis is headquartered

Location

Headquarters

HQ city
Oberhaching
HQ country
Germany
HQ region
Europe

Offices3 records

Markets served

Bendalis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Sale of sterile oncology medicines, generic cancer drugs, supportive care products, and specialist therapeutics to hospitals, clinics, and healthcare providers. Products include 5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Epirubicin, Gemcitabine, Irinotecan, Octreotide, Oxaliplatin, Vinorelbine, Zoledronic acid, Ibandronic acid, Bendafolin, Sugammadex, Vancomycin, Somatostatin Lyomark 3 mg, and the AgainLife supportive care product line. Revenue is generated through direct sales and distribution partnerships globally.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Bendalis product offering

Product offering

Core offering

Bendalis manufactures and markets a broad portfolio of generic sterile oncology chemotherapy agents (5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine), supportive care products (Bendafolin, the AgainLife product line based on Adelmidrol, KapDolen), and specialty therapeutics (Sugammadex, Somatostatin Lyomark 3 mg, Vancomycin). Products are produced to European GMP/GDP quality standards at sterile manufacturing sites in Germany and Spain and supplied to hospitals, oncology clinics, hospital pharmacies, and clinical trial sponsors across Europe, North America and Asia.

Product overview

Bendalis is a specialty pharmaceutical company focused on the development and marketing of high-quality generic oncology drugs and supportive care products for the hospital sector. The company operates a diversified portfolio centered around three main product categories: (1) Core Oncology Products - a broad range of established generic chemotherapy agents including 5-Fluorouracil (5FU), Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine, Octreotide, Zoledronic acid, Ibandronic acid, Somatostatin Lyomark 3 mg, and Sugammadex (acquired 2025); (2) Supportive Care Products including Bendafolin (folinic acid), the Again-Life sub-brand product line (OraLife, TraLife, RaLife, EvaLife, GutLife) for skin and mucous membrane protection using Adelmidrol, KapDolen for nerve fibre relief, and distributed products Caphosol (oral mucositis) and ALOXI (antiemetic); and (3) Antibiotics including Vancomycin. Products are manufactured to European quality standards with GMP and GDP certification and are distributed primarily to hospitals and clinical settings across Europe and internationally.

Differentiator

Problem solved

Functional benefit

Brands

  • AgainLife: Supportive care product line including OraLife, TraLife, RaLife, EvaLife, and GutLife.

Products and services

  • 5-Fluorouracil (5FU) Generic fluoropyrimidine chemotherapy medication used in the treatment of various solid tumours including colorectal, gastric, breast, and pancreatic cancers; available in 10-pack presentations.
  • Carboplatin Generic platinum-based chemotherapy agent used to treat ovarian cancer, lung cancer, and other solid tumours.
  • Doxorubicin Anthracycline chemotherapy medication used to treat a wide range of cancers including bladder, breast, lymphoma, and other malignancies.
  • Methotrexate Antimetabolite and antifolate chemotherapy drug used in various cancers and autoimmune conditions, also used in oncology supportive care.
  • Paclitaxel Taxane chemotherapy medication used to treat various solid tumours including breast, ovarian, and lung cancer.
  • Docetaxel Taxane chemotherapy medication used in breast, lung, and prostate cancer; supplied via Inceptua for global clinical trial use.
  • Gemcitabine Nucleoside analog chemotherapy used in pancreatic, breast, lung, ovarian, and bladder cancer; supplied via Inceptua for clinical trial use.
  • Epirubicin Anthracycline chemotherapy medication used primarily in breast cancer and other solid tumours.
  • Irinotecan Topoisomerase I inhibitor chemotherapy used primarily in metastatic colorectal cancer; supplied via Inceptua for clinical trial use.
  • Oxaliplatin Platinum-based chemotherapy used in combination regimens for colorectal cancer; supplied via Inceptua for clinical trial use.
  • Vinorelbine Vinca alkaloid chemotherapy used primarily in non-small cell lung cancer and breast cancer; supplied via Inceptua for clinical trial use.
  • Octreotide Synthetic somatostatin analog used in the treatment of neuroendocrine tumours, acromegaly, and related conditions.
  • Zoledronic acid Bisphosphonate used to treat bone metastases and tumour-induced hypercalcemia of malignancy.
  • Ibandronic acid Bisphosphonate used in oncology-related bone metastases and osteoporosis care.
  • Somatostatin Lyomark 3 mg Somatostatin analog supplied in 3 mg vials for treatment of neuroendocrine tumours, gastrointestinal bleeding, and related hospital indications.
  • Sugammadex Selective relaxant binding agent used to reverse neuromuscular blockade induced by rocuronium or vecuronium during surgery; now distributed globally by Bendalis with full worldwide rights.
  • Vancomycin Bendalis Glycopeptide antibiotic supplied in 500 mg and 1000 mg 10-packs for treatment of serious Gram-positive infections in hospital settings.
  • Bendafolin (Folinic acid) Folinic acid (leucovorin) used as rescue therapy after high-dose methotrexate and to enhance 5-fluorouracil activity in colorectal cancer regimens.
  • AgainLife Product Line (OraLife, TraLife, RaLife, EvaLife, GutLife) Medical device product line for skin and mucous membrane protection during cancer therapy, based on the patented active ingredient Adelmidrol; includes OraLife and TraLife (oral rinses/sprays), RaLife (skin cream), EvaLife (vaginal gel), and GutLife (anal cream).
  • KapDolen Supportive care product for relief of damaged tissues and nerve fibres in cancer patients; available in 30 ml and 100 ml presentations.
  • Caphosol Calcium phosphate oral rinse distributed by Bendalis (in partnership with EUSA Pharma) for the management of oral mucositis caused by cancer therapy.
  • ALOXI (Palonosetron) Innovative 5-HT3 receptor antagonist used for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV); co-promoted by Bendalis with Riemser Arzneimittel AG in Germany.

Companies that use Bendalis

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Bendalis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Bendalis partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Biofactor GmbHcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Bendalis GmbH acquired the product Sugammadex completely including all global distribution rights from Biofactor GmbH effective 1 January 2025. All existing customer relationships, contractual rights, and distribution structures transferred to Bendalis, creating a single point of contact for supply, quality, and support worldwide. The acquisition marks a significant expansion of Bendalis international activities.
  • Inresa Arzneimittel GmbHcoreChannel Partner/ Reseller/ Distributor · 8 December 2023Bendalis GmbH partnered with Inresa Arzneimittel GmbH as the distribution and sales partner for Somatostatin Lyomark 3 mg in Germany. Inresa was chosen as a strategic distributor to ensure continued supply of Somatostatin and maintain patient care. The product is now supplied in vials instead of ampoules, improving safety and reducing glass breakage. Inresa is established in hospitals and known for reliable on-time deliveries.
  • Inceptua GroupcoreChannel Partner/ Reseller/ Distributor · 25 November 2019Bendalis entered an exclusive agreement with Inceptua Group (formerly Multipharma GmbH) for the supply of clinical trial material for generic oncology products. Inceptua became the exclusive worldwide distributor of Bendalis products for clinical trials, offering sponsors rapid access to Brexit-compliant oncology standard of care medicines manufactured within the EU. Products include Carboplatin, Docetaxel, Gemcitabine, Paclitaxel, Oxaliplatin, Vinorelbine, Irinotecan, and Fluorouracil (5FU). The partnership enables Bendalis to serve clinical trial sponsors globally through Inceptua's established network.
  • Lyomark Pharma GmbHcoreStrategic or Co-development PartnerLyomark Pharma GmbH is the sister company of Bendalis, founded in 1989 in Oberhaching near Munich as a contract and active ingredient manufacturer for niche products. Lyomark provides lyophilised and liquid sterile product manufacturing services to Bendalis. Services include dossier provision, maintenance, and submission of national and international approvals for pharmaceutical companies. The companies share management (Dr. Wolfgang Burger and Dr. Dirk Hütten serve as Managing Directors of both entities).
  • EUSA Pharma GmbHminorChannel Partner/ Reseller/ DistributorIn 2008, Bendalis entered a collaboration with EUSA Pharma GmbH for the distribution of Caphosol for the treatment of oral mucositis, a supportive care product for cancer patients.
  • Riemser Arzneimittel AGminorGTM or Marketing PartnerFrom the beginning of 2011, Bendalis had a co-promotion agreement with Riemser Arzneimittel AG for Aloxi (Palonosetron), an innovative 5-HT3 receptor antagonist for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This partnership was for the German market.
  • European, North American and Asian Strategic PartnersminorStrategic or Co-development PartnerBendalis has strategic alliances with partners in Europe, North America and Asia to continuously expand global reach. These partnerships focus on collaborative innovation to drive new therapies and standards in oncology. The company is seeking additional partners who share their values to advance oncology therapeutics.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Bendalis competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Bendalis social profiles

Digital presence

Bendalis compliance and trust

Trust signal

Compliance4 records

Bendalis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bendalis leadership team

Management profile

Number of profiles

Profiles3 records

Bendalis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bendalis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bendalis

What does Bendalis do?

Bendalis manufactures and markets a broad portfolio of generic sterile oncology chemotherapy agents (5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine), supportive care products (Bendafolin, the AgainLife product line based on Adelmidrol, KapDolen), and specialty therapeutics (Sugammadex, Somatostatin Lyomark 3 mg, Vancomycin). Products are produced to European GMP/GDP quality standards at sterile manufacturing sites in Germany and Spain and supplied to hospitals, oncology clinics, hospital pharmacies, and clinical trial sponsors across Europe, North America and Asia.

Is Bendalis a public or private company?

Bendalis is a private company. It is classified as unknown and is currently operating.

When was Bendalis founded?

Bendalis was founded in 2006. It employs 11 to 50 people.

Where is Bendalis based?

Bendalis is headquartered in Oberhaching, Germany, in the Europe region.

How does Bendalis make money?

One revenue line is on record: pharmaceutical Product Sales.

Does Bendalis have an API?

No public API is recorded for Bendalis.

What industry is Bendalis in?

Bendalis's product category is Specialty Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales